Additional Information

Description

Xeljanz Xr 11 mg tablet is an oral Janus kinase (JAK) inhibitor indicated for the treatment of autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and ankylosing spondylitis. It modulates immune signaling pathways by selectively inhibiting JAK enzymes, thereby reducing inflammatory responses associated with these chronic diseases.

The active ingredient, tofacitinib, inhibits JAK1 and JAK3, thereby disrupting cytokine-mediated signaling involved in immune activation. By suppressing overactive immune responses, Xeljanz reduces joint inflammation, prevents structural damage in arthritis, and controls mucosal inflammation in ulcerative colitis. As an oral small-molecule therapy, it offers an alternative to biologic disease-modifying antirheumatic drugs (DMARDs).

Xeljanz is administered orally, typically twice daily, with or without food. Dosage adjustments may be necessary in patients with renal or hepatic impairment. Routine monitoring is required to assess liver enzymes, lipid levels, and complete blood counts due to risks of infection, thrombosis, and hematologic abnormalities.